Benitec Biopharma Inc. financial data

Symbol
BNTC on Nasdaq
Location
3940 Trust Way, Hayward, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.7K % +225%
Debt-to-equity 4.25 % -68.9%
Return On Equity -37.9 % +37.2%
Return On Assets -36.3 % +31.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.3M shares +149%
Common Stock, Shares, Outstanding 26.3M shares +46.7%
Entity Public Float 153M USD +1727%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 41.5M shares +48.9%
Weighted Average Number of Shares Outstanding, Diluted 41.5M shares +48.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 17.3M USD +17.1%
General and Administrative Expense 21.1M USD +177%
Operating Income (Loss) -38.4M USD -71.5%
Nonoperating Income (Expense) 3.95M USD +155%
Net Income (Loss) Attributable to Parent -34.5M USD -65.3%
Earnings Per Share, Basic -1 USD/shares -161%
Earnings Per Share, Diluted -1 USD/shares -161%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 94.5M USD +39.3%
Other Assets, Current 480K USD +12.7%
Assets, Current 95.1M USD +39.1%
Property, Plant and Equipment, Net 118K USD -23.4%
Operating Lease, Right-of-Use Asset 755K USD +270%
Other Assets, Noncurrent 20K USD -64.3%
Assets 96M USD +39.6%
Employee-related Liabilities, Current 463K USD -6.47%
Liabilities, Current 2.03M USD -55.5%
Operating Lease, Liability, Noncurrent 403K USD
Liabilities 2.43M USD -47.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -750K USD +24.5%
Retained Earnings (Accumulated Deficit) -237M USD -21.4%
Stockholders' Equity Attributable to Parent 93.6M USD +45.8%
Liabilities and Equity 96M USD +39.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.35M USD +26.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 160M shares 0%
Common Stock, Shares, Issued 26.3M shares +46.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.27M USD -119%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 94.6M USD +39.3%
Deferred Tax Assets, Valuation Allowance 25M USD +21.6%
Deferred Tax Assets, Gross 25.5M USD +21.9%
Operating Lease, Liability 817K USD +287%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.2M USD -62.5%
Lessee, Operating Lease, Liability, to be Paid 866K USD +303%
Property, Plant and Equipment, Gross 1.6M USD +1.14%
Operating Lease, Liability, Current 414K USD +96.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 291K USD -3.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 100K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 49K USD +1125%
Deferred Tax Assets, Operating Loss Carryforwards 16.5M USD +13.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares
Operating Lease, Payments 32K USD -56.2%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 54K USD -41.9%
Share-based Payment Arrangement, Expense 22.2M USD +1789%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares